Skip to main content
Fig. 4 | Orphanet Journal of Rare Diseases

Fig. 4

From: Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial

Fig. 4

Spleen volume in multiples of normal (MN) during placebo or olipudase alfa treatment periods. Means are shown above and below the lines for the group crossing over to olipudase alfa from placebo and the olipudase alfa group, respectively. Splenomegaly severity cutoffs are indicated by the dashed lines [26]

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172